James E Flynn Insider Trading $ATRS ANTARES PHARMA, INC.
Get free email notifications about insider trading for James E Flynn.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of James E Flynn. James E Flynn is 10% Owner in CAS MEDICAL SYSTEMS INC ($CAMY.OB) and 10% Owner in AxoGen, Inc. ($LECT) and 10% Owner in PAR PHARMACEUTICAL COMPANIES, INC. ($PRX) and 10% Owner in Fibrocell Science, Inc. ($FCSC) and 10% Owner in STREAMLINE HEALTH SOLUTIONS INC. ($LANV) and 10% Owner in ANTARES PHARMA, INC. ($ATRS) and 10% Owner in VIA Pharmaceuticals, Inc. ($CAQ) and 10% Owner in DUSA PHARMACEUTICALS INC ($DUSA) and 10% Owner in HI TECH PHARMACAL CO INC ($HITK) and 10% Owner in AVADEL PHARMACEUTICALS PLC ($AVDL) and 10% Owner in INSPIRE PHARMACEUTICALS INC ($ISPH) and 10% Owner in RIGEL PHARMACEUTICALS INC ($RIGL) and 10% Owner in ARENA PHARMACEUTICALS INC ($ARNA) and 10% Owner in ISTA PHARMACEUTICALS INC ($ISTA) and 10% Owner in MEDICINES CO /DE ($MDCO) and 10% Owner in THIRD WAVE TECHNOLOGIES INC /WI ($TWTI) and 10% Owner in DYNAVAX TECHNOLOGIES CORP ($DVAX) and 10% Owner in Cyclacel Pharmaceuticals, Inc. ($CYCC) and Director in Talon Therapeutics, Inc. ($EMLR) and 10% Owner in LUMOS PHARMA, INC. ($NLNK) and 10% Owner in NITROMED INC ($NTMD) and 10% Owner in XENOPORT INC ($XNPT) and 10% Owner in EMAGEON INC ($EMAG) and 10% Owner in CATALYST BIOSCIENCES, INC. ($CBIO) and 10% Owner in ALIMERA SCIENCES INC ($ALIM) and 10% Owner in NeuroMetrix, Inc. ($NURO) and 10% Owner in NxStage Medical, Inc. ($NXTM) and 10% Owner in aTYR PHARMA INC ($LIFE) and 10% Owner in Vanda Pharmaceuticals Inc. ($VNDA) and 10% Owner in XERIS PHARMACEUTICALS INC ($XERS) and Director in PROTEON THERAPEUTICS INC ($PRTO) and 10% Owner in eHealth, Inc. ($EHTH) and 10% Owner in ZAFGEN, INC. ($ZFGN) and 10% Owner in NeurogesX Inc ($NGSX) and 10% Owner in Invuity, Inc. ($IVTY) and 10% Owner in Dicerna Pharmaceuticals Inc ($DRNA) and 10% Owner in CONSTELLATION PHARMACEUTICALS INC ($CNST) and 10% Owner in TriVascular Technologies, Inc. ($TRIV) and 10% Owner in Auspex Pharmaceuticals, Inc. ($ASPX) and 10% Owner in Neos Therapeutics, Inc. ($NEOS) and 10% Owner in Schrodinger, Inc. ($SDGR) and 10% Owner in CytomX Therapeutics, Inc. ($CTMX) and Director in Acutus Medical, Inc. ($AFIB) and 10% Owner in Annexon, Inc. ($ANNX) and 10% Owner in Aclaris Therapeutics, Inc. ($ACRS) and 10% Owner in Syros Pharmaceuticals, Inc. ($SYRS) and 10% Owner in Mallinckrodt plc ($MNK) and 10% Owner in Loxo Oncology, Inc. ($LOXO) and 10% Owner in Adverum Biotechnologies, Inc. ($AAVL) and 10% Owner in REGENXBIO Inc. ($RGNX) and 10% Owner in Recro Pharma, Inc. ($REPH) and 10% Owner in Nivalis Therapeutics, Inc. ($NVLS) and Director in Nivalis Therapeutics, Inc. ($NVLS) and 10% Owner in Audentes Therapeutics, Inc. ($BOLD) and 10% Owner in SteadyMed Ltd. ($STDY) and 10% Owner in ShockWave Medical, Inc. ($SWAV) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and 10% Owner in Editas Medicine, Inc. ($EDIT) and Director in AveXis, Inc. ($AVXS) and 10% Owner in ARVINAS INC. ($ARVN) and 10% Owner in Homology Medicines, Inc. ($FIXX) and Director in Homology Medicines, Inc. ($FIXX) and Director in Oncorus, Inc. ($ONCR) and 10% Owner in Revolution Medicines, Inc. ($RVMD) and 10% Owner in Black Diamond Therapeutics, Inc. ($BDTX) and 10% Owner in Frequency Therapeutics, Inc. ($FREQ) and Director in DFB Healthcare Acquisitions Corp. ($DFBH) and 10% Owner in Generation Bio Co. ($GBIO) and 10% Owner in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and 10% Owner in Mirum Pharmaceuticals, Inc. ($MIRM) and 10% Owner in Cabaletta Bio, Inc. ($CABA) and 10% Owner in Werewolf Therapeutics, Inc. ($HOWL) and 10% Owner in Nkarta, Inc. ($NKTX) and 10% Owner in Edgewise Therapeutics, Inc. ($EWTX) and Director in DFP HEALTHCARE ACQUISITIONS CORP. ($DFPH) and Director in Deerfield Healthcare Technology Acquisitions Corp. ($DFHT) and 10% Owner in Terns Pharmaceuticals, Inc. ($TERN).
James E Flynn in ANTARES PHARMA, INC.
Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
Position of James E Flynn: 10% Owner
Holdings: 5,348,776 shares
Current Value: $11,767,307
Latest Transaction: Sep 30 2015
$ATRS Market Capitalization: $356.70M
$ATRS Previous Close: $2.20
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of James E Flynn in ANTARES PHARMA, INC.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACRS, AFIB, DFBH, ADVM, ALIM, ALPN, ANNX, ATRS, ARNA, ARVN, LIFE, BOLD, ASPX, AVDL, AVXS, LECT, BDTX, CABA, CAMY.OB, CBIO, CNST, CYCC, CTMX, DFHTW, DFPHU, DRNA, DUSA, DVAX, EWTX, EDIT, EHTH, EMAG, FCSC, FREQ, GBIO, HITK, FIXX, ISPH, IVTY, ISTA, KNSA, LRMR, LOXO, NLNK, MNK, MDCO, MIRM, NEOS, NGSX, NURO, NTMD, NKTX, NXTM, ONCR, PRX, TARA, REPH, RGNX, RVMD, RYTM, RIGL, SDGR, SWAV, STDY, LANV, SYRS, EMLR, TERN, TWTI, TRIV, VNDA, CAQ, HOWL, XNPT, XERS
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.69 | 83,930 | 142,018 | 5,348,776 | 5.4 M to 5.3 M (-1.54 %) |
| Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.69 | 106,820 | 180,750 | 6,807,533 | 6.9 M to 6.8 M (-1.54 %) |
| Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.69 | 59,248 | 100,254 | 3,294,817 | 3.4 M to 3.3 M (-1.77 %) |
| Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.83 | 34,450 | 63,044 | 5,432,706 | 5.5 M to 5.4 M (-0.63 %) |
| Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.83 | 43,845 | 80,236 | 6,914,353 | 7 M to 6.9 M (-0.63 %) |
| Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.82 | 11,081 | 20,176 | 3,354,065 | 3.4 M to 3.4 M (-0.33 %) |
| Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.82 | 15,696 | 28,579 | 5,467,156 | 5.5 M to 5.5 M (-0.29 %) |
| Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.82 | 19,976 | 36,372 | 6,958,198 | 7 M to 7 M (-0.29 %) |
| Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.81 | 23,700 | 42,897 | 3,365,146 | 3.4 M to 3.4 M (-0.70 %) |
| Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.81 | 33,572 | 60,765 | 5,482,852 | 5.5 M to 5.5 M (-0.61 %) |
| Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.81 | 42,728 | 77,338 | 6,978,174 | 7 M to 7 M (-0.61 %) |
| Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.81 | 368,676 | 669,036 | 5,516,424 | 5.9 M to 5.5 M (-6.26 %) |
| Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.81 | 469,224 | 851,501 | 7,020,902 | 7.5 M to 7 M (-6.26 %) |
| Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.80 | 226,857 | 408,774 | 5,885,100 | 6.1 M to 5.9 M (-3.71 %) |
| Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.80 | 288,726 | 520,255 | 7,490,126 | 7.8 M to 7.5 M (-3.71 %) |
| Jul 21 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.14 | 31,261 | 66,995 | 6,111,957 | 6.1 M to 6.1 M (-0.51 %) |
| Jul 21 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.14 | 39,787 | 85,268 | 7,778,852 | 7.8 M to 7.8 M (-0.51 %) |
| Jul 21 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.13 | 4,048 | 8,622 | 6,143,218 | 6.1 M to 6.1 M (-0.07 %) |
| Jul 21 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.13 | 5,152 | 10,974 | 7,818,639 | 7.8 M to 7.8 M (-0.07 %) |
| Jul 21 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.12 | 3,245 | 6,879 | 6,147,266 | 6.2 M to 6.1 M (-0.05 %) |
| Jul 21 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.12 | 4,131 | 8,758 | 7,823,791 | 7.8 M to 7.8 M (-0.05 %) |
| Jul 21 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.11 | 8,096 | 17,083 | 6,150,511 | 6.2 M to 6.2 M (-0.13 %) |
| Jul 21 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.11 | 10,304 | 21,741 | 7,827,922 | 7.8 M to 7.8 M (-0.13 %) |
| Jul 21 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.20 | 55,338 | 121,921 | 6,158,607 | 6.2 M to 6.2 M (-0.89 %) |
| Jul 21 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.20 | 70,431 | 155,174 | 7,838,226 | 7.9 M to 7.8 M (-0.89 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.07 | 19,598 | 40,501 | 6,213,945 | 6.2 M to 6.2 M (-0.31 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.07 | 24,943 | 51,547 | 7,908,657 | 7.9 M to 7.9 M (-0.31 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.06 | 43,956 | 90,330 | 6,233,543 | 6.3 M to 6.2 M (-0.70 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.06 | 55,944 | 114,965 | 7,933,600 | 8 M to 7.9 M (-0.70 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.05 | 43,956 | 89,890 | 6,277,499 | 6.3 M to 6.3 M (-0.70 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.05 | 55,944 | 114,405 | 7,989,544 | 8 M to 8 M (-0.70 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.06 | 44,000 | 90,420 | 6,321,455 | 6.4 M to 6.3 M (-0.69 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.06 | 56,000 | 115,080 | 8,045,488 | 8.1 M to 8 M (-0.69 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.05 | 44,000 | 89,980 | 6,365,455 | 6.4 M to 6.4 M (-0.69 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.05 | 56,000 | 114,520 | 8,101,488 | 8.2 M to 8.1 M (-0.69 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.10 | 41,650 | 87,369 | 6,409,455 | 6.5 M to 6.4 M (-0.65 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.10 | 53,009 | 111,197 | 8,157,488 | 8.2 M to 8.2 M (-0.65 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.09 | 24,108 | 50,395 | 6,451,105 | 6.5 M to 6.5 M (-0.37 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.09 | 30,684 | 64,142 | 8,210,497 | 8.2 M to 8.2 M (-0.37 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.09 | 2,244 | 4,679 | 6,475,213 | 6.5 M to 6.5 M (-0.03 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.09 | 2,856 | 5,955 | 8,241,181 | 8.2 M to 8.2 M (-0.03 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.09 | 3,476 | 7,247 | 6,477,457 | 6.5 M to 6.5 M (-0.05 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.09 | 4,424 | 9,224 | 8,244,037 | 8.2 M to 8.2 M (-0.05 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.08 | 15,928 | 33,130 | 6,480,933 | 6.5 M to 6.5 M (-0.25 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.08 | 20,272 | 42,166 | 8,248,461 | 8.3 M to 8.2 M (-0.25 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.12 | 67,577 | 143,371 | 6,496,861 | 6.6 M to 6.5 M (-1.03 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.12 | 86,007 | 182,472 | 8,268,733 | 8.4 M to 8.3 M (-1.03 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.12 | 16,689 | 35,362 | 6,564,438 | 6.6 M to 6.6 M (-0.25 %) |
| Jul 08 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.12 | 21,240 | 45,005 | 8,354,740 | 8.4 M to 8.4 M (-0.25 %) |
| Jul 01 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.11 | 4,664 | 9,841 | 6,581,127 | 6.6 M to 6.6 M (-0.07 %) |
| Jul 01 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.11 | 5,936 | 12,525 | 8,375,980 | 8.4 M to 8.4 M (-0.07 %) |
| Jul 01 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.10 | 14,624 | 30,735 | 6,585,791 | 6.6 M to 6.6 M (-0.22 %) |
| Jul 01 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.10 | 18,612 | 39,117 | 8,381,916 | 8.4 M to 8.4 M (-0.22 %) |
| Jul 01 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.08 | 136,170 | 283,887 | 6,600,415 | 6.7 M to 6.6 M (-2.02 %) |
| Jul 01 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.08 | 173,307 | 361,310 | 8,400,528 | 8.6 M to 8.4 M (-2.02 %) |
| Jul 01 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.08 | 69,914 | 145,757 | 3,388,846 | 3.5 M to 3.4 M (-2.02 %) |
| Jul 01 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.08 | 82,300 | 170,962 | 6,736,585 | 6.8 M to 6.7 M (-1.21 %) |
| Jul 01 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.08 | 104,745 | 217,587 | 8,573,835 | 8.7 M to 8.6 M (-1.21 %) |
| Jul 01 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.08 | 42,255 | 87,776 | 3,458,760 | 3.5 M to 3.5 M (-1.21 %) |
| Jul 01 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.18 | 21,784 | 47,406 | 6,818,885 | 6.8 M to 6.8 M (-0.32 %) |
| Jul 01 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.18 | 27,726 | 60,337 | 8,678,580 | 8.7 M to 8.7 M (-0.32 %) |
| Jul 01 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.18 | 11,185 | 24,341 | 3,501,015 | 3.5 M to 3.5 M (-0.32 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.24 | 79,586 | 178,098 | 6,853,826 | 6.9 M to 6.9 M (-1.15 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.24 | 101,291 | 226,669 | 8,723,052 | 8.8 M to 8.7 M (-1.15 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.24 | 33,627 | 75,251 | 3,518,297 | 3.6 M to 3.5 M (-0.95 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.25 | 38,598 | 86,876 | 6,933,412 | 7 M to 6.9 M (-0.55 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.25 | 49,124 | 110,568 | 8,824,343 | 8.9 M to 8.8 M (-0.55 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.25 | 16,308 | 36,706 | 3,551,924 | 3.6 M to 3.6 M (-0.46 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.25 | 37,919 | 85,318 | 6,972,010 | 7 M to 7 M (-0.54 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.25 | 48,260 | 108,585 | 8,873,467 | 8.9 M to 8.9 M (-0.54 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.25 | 16,021 | 36,047 | 3,568,232 | 3.6 M to 3.6 M (-0.45 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.25 | 27,085 | 60,941 | 7,009,929 | 7 M to 7 M (-0.38 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.25 | 34,471 | 77,560 | 8,921,727 | 9 M to 8.9 M (-0.38 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.25 | 11,444 | 25,749 | 3,584,253 | 3.6 M to 3.6 M (-0.32 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.34 | 27,164 | 63,466 | 7,037,014 | 7.1 M to 7 M (-0.38 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.34 | 34,572 | 80,774 | 8,956,198 | 9 M to 9 M (-0.38 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.34 | 11,477 | 26,815 | 3,595,697 | 3.6 M to 3.6 M (-0.32 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.30 | 29,214 | 67,192 | 7,064,178 | 7.1 M to 7.1 M (-0.41 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.30 | 37,181 | 85,516 | 8,990,770 | 9 M to 9 M (-0.41 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.30 | 12,344 | 28,391 | 3,607,174 | 3.6 M to 3.6 M (-0.34 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.29 | 41,245 | 94,418 | 7,093,392 | 7.1 M to 7.1 M (-0.58 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.29 | 52,494 | 120,169 | 9,027,951 | 9.1 M to 9 M (-0.58 %) |
| Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.29 | 17,427 | 39,894 | 3,619,518 | 3.6 M to 3.6 M (-0.48 %) |
| Jun 23 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.35 | 67,475 | 158,499 | 7,134,637 | 7.2 M to 7.1 M (-0.94 %) |
| Jun 23 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.35 | 85,877 | 201,725 | 9,080,445 | 9.2 M to 9.1 M (-0.94 %) |
| Jun 23 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.35 | 28,510 | 66,970 | 3,636,945 | 3.7 M to 3.6 M (-0.78 %) |
| Jun 23 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 65,479 | 157,569 | 7,202,112 | 7.3 M to 7.2 M (-0.90 %) |
| Jun 23 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 83,338 | 200,545 | 9,166,322 | 9.2 M to 9.2 M (-0.90 %) |
| Jun 23 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 27,666 | 66,575 | 3,665,455 | 3.7 M to 3.7 M (-0.75 %) |
| Jun 23 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 52,518 | 126,337 | 7,267,591 | 7.3 M to 7.3 M (-0.72 %) |
| Jun 23 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 66,842 | 160,795 | 9,249,660 | 9.3 M to 9.2 M (-0.72 %) |
| Jun 23 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 22,190 | 53,380 | 3,693,121 | 3.7 M to 3.7 M (-0.60 %) |
| Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 1,447 | 3,589 | 7,320,109 | 7.3 M to 7.3 M (-0.02 %) |
| Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 1,842 | 4,568 | 9,316,502 | 9.3 M to 9.3 M (-0.02 %) |
| Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 611 | 1,515 | 3,715,311 | 3.7 M to 3.7 M (-0.02 %) |
| Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 76,728 | 189,948 | 7,321,556 | 7.4 M to 7.3 M (-1.04 %) |
| Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 97,654 | 241,752 | 9,318,344 | 9.4 M to 9.3 M (-1.04 %) |
| Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 32,419 | 80,256 | 3,715,922 | 3.7 M to 3.7 M (-0.86 %) |
| Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 19,889 | 47,839 | 7,398,284 | 7.4 M to 7.4 M (-0.27 %) |
| Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 25,313 | 60,885 | 9,415,998 | 9.4 M to 9.4 M (-0.27 %) |
| Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 8,403 | 20,212 | 3,748,341 | 3.8 M to 3.7 M (-0.22 %) |
| Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 43,506 | 104,506 | 7,418,173 | 7.5 M to 7.4 M (-0.58 %) |
| Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 55,372 | 133,009 | 9,441,311 | 9.5 M to 9.4 M (-0.58 %) |
| Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 18,382 | 44,155 | 3,756,744 | 3.8 M to 3.8 M (-0.49 %) |
| Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 35,915 | 86,322 | 7,461,679 | 7.5 M to 7.5 M (-0.48 %) |
| Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 45,710 | 109,864 | 9,496,683 | 9.5 M to 9.5 M (-0.48 %) |
| Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 15,175 | 36,473 | 3,775,126 | 3.8 M to 3.8 M (-0.40 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 22,973 | 55,144 | 3,790,301 | 3.8 M to 3.8 M (-0.60 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 5,267 | 12,641 | 3,813,274 | 3.8 M to 3.8 M (-0.14 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 1,568 | 3,771 | 3,818,541 | 3.8 M to 3.8 M (-0.04 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 54,370 | 130,510 | 7,497,594 | 7.6 M to 7.5 M (-0.72 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 69,198 | 166,103 | 9,542,393 | 9.6 M to 9.5 M (-0.72 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 12,467 | 29,921 | 7,551,964 | 7.6 M to 7.6 M (-0.16 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 15,866 | 38,078 | 9,611,591 | 9.6 M to 9.6 M (-0.16 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 3,710 | 8,923 | 7,564,431 | 7.6 M to 7.6 M (-0.05 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 4,722 | 11,356 | 9,627,457 | 9.6 M to 9.6 M (-0.05 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.43 | 44,010 | 106,874 | 7,568,141 | 7.6 M to 7.6 M (-0.58 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.43 | 56,012 | 136,020 | 9,632,179 | 9.7 M to 9.6 M (-0.58 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.43 | 18,551 | 44,986 | 7,612,151 | 7.6 M to 7.6 M (-0.24 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.43 | 23,611 | 57,257 | 9,688,191 | 9.7 M to 9.7 M (-0.24 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.43 | 18,551 | 44,986 | 7,630,702 | 7.6 M to 7.6 M (-0.24 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.43 | 23,611 | 57,257 | 9,711,802 | 9.7 M to 9.7 M (-0.24 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.43 | 18,595 | 45,156 | 3,820,109 | 3.8 M to 3.8 M (-0.48 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.43 | 7,838 | 19,007 | 3,838,704 | 3.8 M to 3.8 M (-0.20 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.43 | 7,838 | 19,007 | 3,846,542 | 3.9 M to 3.8 M (-0.20 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.47 | 67,627 | 166,782 | 7,649,253 | 7.7 M to 7.6 M (-0.88 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.47 | 86,071 | 212,268 | 9,735,413 | 9.8 M to 9.7 M (-0.88 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 58,251 | 144,445 | 7,716,880 | 7.8 M to 7.7 M (-0.75 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 74,137 | 183,838 | 9,821,484 | 9.9 M to 9.8 M (-0.75 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.47 | 28,574 | 70,469 | 3,854,380 | 3.9 M to 3.9 M (-0.74 %) |
| Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 24,612 | 61,030 | 3,882,954 | 3.9 M to 3.9 M (-0.63 %) |
Page: 1